Tag: Genentech

With a list price of approximately $2,300 per treatment as of early 2025, many patients and healthcare providers ask: why does Vabysmo cost so much?. The answer lies in the complex ecosystem of pharmaceutical pricing, which includes everything from advanced research and development to market competition and distribution costs.

In October 2022, Genentech voluntarily recalled its Susvimo ocular implant, a novel treatment for wet age-related macular degeneration (AMD), just a year after its FDA approval. The recall was initiated after some implants failed quality performance standards during testing, providing the definitive answer to **why was Susvimo recalled**.

Susvimo was first FDA-approved in October 2021 for wet age-related macular degeneration, but a voluntary recall in 2022 due to manufacturing issues created a temporary hurdle. Today, following a successful relaunch in 2024, Susvimo is not only FDA-approved but also carries multiple indications for treating serious retinal conditions.

First approved by the FDA in 1997, rituximab has since revolutionized the treatment of several B-cell cancers and autoimmune diseases. The journey to market involved multiple companies, and today, an expanding list of manufacturers produce this essential medicine. So, which company makes rituximab, and what do you need to know about the different versions?

In August 2024, Genentech confirmed the discontinuation of the HIV medication Fuzeon (enfuvirtide) in the United States, effective February 28, 2025. This change is primarily driven by evolving clinical practices and a reduced medical need for the drug, with numerous newer alternative treatments now available.

Rozlytrek (entrectinib) received its initial accelerated approval from the U.S. Food and Drug Administration (FDA) in August 2019 for specific types of cancer. The answer to who makes Rozlytrek involves a complex history of development and acquisition, leading to the current manufacturer, Genentech, a member of the Roche Group.